Evofem Biosciences Inc. Reports 16% Increase in Q2 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)

Reuters2025-08-14
<a href="https://laohu8.com/S/EVFM">Evofem Biosciences</a> Inc. Reports 16% Increase in <a href="https://laohu8.com/S/QTWO">Q2</a> 2025 Net Sales; Net Loss of $1.8M and EPS of $(0.02)

Evofem Biosciences Inc. has reported its financial results for the second quarter of 2025, revealing an increase in net sales to $4.8 million, up from $4.2 million in the same period last year. The company also showed an improvement in its loss from operations, which decreased to $1.3 million from $1.4 million in the prior year quarter. However, the net loss attributable to common stockholders was $1.8 million, compared to a net income of $1.3 million in the second quarter of 2024. Evofem's CEO, Saundra Pelletier, expressed optimism about future sales, attributing anticipated growth to upcoming social media initiatives and positive press coverage for PHEXXI. The company continues to implement fiscal austerity measures but remains confident in its strategic direction. Total operating expenses for the quarter rose to $6.1 million from $5.5 million in the previous year, influenced by increased selling and marketing expenses, partially due to the Prescription Drug User Fee Act (PDUFA) fee for SOLOSEC, and higher R&D expenses related to the same acquisition. Despite these increases, general and administrative expenses saw a decrease of $0.4 million.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Evofem Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA51293) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment